Should I Buy INTS? INTS 2026 Analysis

Should You Buy Intensity Therapeutics Inc (INTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.370

1 Day change

-3.67%

52 Week Range

2.530

Analysis Updated At

2026/01/26

Intensity Therapeutics Inc (INTS) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock shows bearish technical indicators, weak financial performance, and lacks significant positive catalysts or trading signals. Given the lack of clear growth trends and no significant news or insider activity, holding off on this investment is advisable until better entry points or stronger fundamentals emerge.

Technical Analysis

The technical indicators for INTS are bearish. The MACD is negatively expanding below 0, the RSI is neutral at 38.589, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 0.415, with support at 0.395 and resistance at 0.434. Overall, the trend suggests downward momentum.

Options Data

Positive Catalysts

NULL identified. There is no recent news, insider trading, or hedge fund activity indicating positive sentiment. Additionally, no recent congress trading data is available.

Neutral/Negative Catalysts

The company's financial performance is weak, with a YoY net income decline of -23.97% and EPS dropping by -76.00%. The stock's technical indicators are bearish, and there is no significant trading activity or news to support a positive outlook.

Financial Performance

In Q3 2025, the company reported zero revenue growth, a net income decline of -23.97% YoY to -$2,671,000, and an EPS drop of -76.00% YoY to -0.06. Gross margin remains at 0%. The financials indicate poor performance and no growth trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes are available for this stock.

3 Analyst Rating

Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.382

Low

1.5

Averages

3.33

High

Current: 0.382

Low

1.5

Averages

3.33

High

Benchmark

Robert Wasserman

Speculative Buy

downgrade

AI Analysis

2025-08-20

Reason

Benchmark

Robert Wasserman

Price Target

AI Analysis

2025-08-20

downgrade

Speculative Buy

Reason

Benchmark analyst Robert Wasserman lowered the firm's price target on Intensity Therapeutics to $1.50 from $4 and keeps a Speculative Buy rating on the shares after the company reported Q2 results and provided an update on their clinical pipeline. The firm cites recent share dilution for its revised price target.

Brookline

Hold

Buy

upgrade

2025-08-12

Reason

Brookline

Price Target

2025-08-12

upgrade

Hold

Buy

Reason

Brookline upgraded Intensity Therapeutics to Buy from Hold with a $3 price target following Q2 results. Raising $11M extends the cash runway to the second half of 2026, notes the firm, which also cites the advancement of the Phase 2 triple negative breast cancer trial. The firm foresees \"a favorable risk-reward as INT230-6 advances through the clinic,\" the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INTS

Unlock Now

INTS Should I Buy

INTS Should I Buy

Should You Buy Intensity Therapeutics Inc (INTS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch